The Philadelphia Department of Public Health (PDPH) released a health advisory on Wednesday, November 15, 2023. Below is a summary.
The demand for nirsevimab (Beyfortus), the monolocal antibody that protects infants against RSV, has exceeded the current manufactured supply for the 2023-24 RSV season.
Providers should prioritize the youngest infants for Beyfortus administration and utilize Synagis for all eligible high-risk infants during the 2023-24 RSV season.
Providers should offer the RSV preF vaccine (Abrysvo) to all pregnant individuals at 32-36 weeks of gestation to protect infants against severe RSV disease in the first 6 months of life.
Most infants born to individuals who have received Abrysvo vaccine will not need a dose of Beyfortus.
